Overview

The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
0
Participant gender:
All
Summary
Patients with comorbidities have an increased risk of ulcer re-bleeding, especially within the 14 days after first bleeding event. Three-day high dose esomeprazole infusion can prevent peptic ulcer rebleeding after endoscopic therapy. However, the optimal dose of oral esomeprazole is uncertain, especially for high risky patients. This study is to test whether a double dose of oral esomprazole could reduce peptic ulcer rebleeding for patients with Rockall score ≥ 6. Additionally, the second aim of this prospective study was to identify the selection criteria to predict poor fading and residual major stigmata of recent hemorrhage (SRH) or early recurrent bleeding after successful endoscopic hemostasis and high-dose PPI infusion.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cheng-Kung University Hospital
Collaborator:
National Science Council, Taiwan
Treatments:
Esomeprazole
Criteria
Inclusion Criteria:

- Patients who received gastroscopy for melena, hematochezia, or hematemesis in whom
bleeding peptic ulcers with major stigmata of recent hemorrhage are detected are
consecutively enrolled. All of these major SRH are treated by local injection of
diluted epinephrine 1:10000 with or without combined therapy with a heater probe,
argon plasma coagulation, band ligation, or hemoclip therapy.

Exclusion Criteria:

- Patients are excluded if they had tumor bleeding or ulcer bleeding due to mechanical
factors (i.e., gastrostomy tube induction), warfarin use, failure to establish
hemostasis under gastroscopy, or hypersensitivity to esomeprazole or any component of
the formulation.